|
Dr. Lundemose was appointed Executive VP OSI Pharmaceuticals Inc. and President (OSI) Prosidion in March 2005 having been the CEO of Prosidion Limited since the Company became operational in February 2003.
Dr. Lundemose is co-founder of several companies including Prosidion Limited and Symphogen A/S. He has broad and extensive experience within Medical Sciences and business obtained from his positions held in both academia and the biotech and pharmaceutical industries. Previous positions include Chief Executive Officer at Pantheco A/S from December 1998 to August 2002 Associate Director Business Development Novo Nordisk from October 1997 to November 1998 Manager Business Development Novo Nordisk from January 1996 to September 1997 and Head of Diabetes Biology Novo Nordisk from June 1994 to December 1995. He received an MD in 1988 from University of Aarhus Denmark and continued at University of Aarhus to 1992 as a Post Doctoral Fellow. During this period in 1992 he was awarded a Wellcome Trust Fellowship at University of Birmingham England. A Ph.D. degree (Molecular Microbiology) was obtained in 1990 and a Doctor of Science (Dr.Med) degree in 1994 both from University of Aarhus Denmark.
Dr. Lundemose holds a Diploma in "Management of Drug and Device Development" from Scandinavian International Management Institute and is a member of the Board of Directors of Prosidion Limited and also OSI Pharmaceuticals (UK) Limited. | 